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Colin Baigent, BM BCHSEE PAGE 2291B lood cholesterol concentration is determinedboth by endogenous cholesterol from hepaticand extrahepatic synthesis and by exogenous
cholesterol derived from intestinal absorption of die-
tary and biliary cholesterol (1). Serum concentrations
of plant sterols (campesterol, sitosterol, and avenas-
terol) and noncholesterol sterols, such as cholestanol,
are markers of intestinal cholesterol absorption efﬁ-
ciency (2).
HMG-CoA reductase inhibitors (statins) work
by inhibiting hepatic cholesterol synthesis and do
not directly affect intestinal absorption. It has
been suggested that patients with a high cholestanol-
to-cholesterol ratio (CR) (i.e., “cholesterol absorbers”)
may be relatively resistant to statin therapy. This
hypothesis was tested among 868 Finnish patients
within the 4S trial (Scandinavian Simvastatin Survival
Study) of simvastatin 20 to 40 mg daily versus pla-
cebo. There was a trend towards smaller effects of
simvastatin on coronary events among those with a
higher CR (rate ratios [RR]: 0.623, 95% conﬁdence
interval [CI]: 0.395 to 0.982 in the ﬁrst quartile [Q1];
0.657, 0.426 to 0.998 in Q2; 0.753, 0.502 to 1.13 in Q3;
and 1.166, 0.791 to 1.72 in Q4) (3). The proportional
reductions in total cholesterol were signiﬁcantly
smaller in Q1 versus Q4 (25.6  0.9% vs. 29.4  0.9%;
p ¼ 0.003). Although the absolute reductions were not
reported, because the baseline total cholesterol was
similar (5.87 to 5.99 mmol/l) among quartiles it may be*Editorials published in the Journal of the American College of Cardiology
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mmol/l smaller in Q1 versus Q4 (4). Meta-analyses
conducted by the CTT (Cholesterol Treatment Tria-
lists) Collaboration (5,6) have shown that the absolute
reduction in low-density lipoprotein (LDL) cholesterol
correlates strongly with the relative reduction in ma-
jor coronary events: each 1 mmol/l (39 mg/dl) lower
LDL cholesterol corresponds to a one-quarter reduc-
tion in risk of major coronary events. A difference of
0.3 mmol/l in the absolute reductions in serum total
cholesterol between quartiles might, therefore, result
in a difference of about 8% in relative risk reductions—
too little to explain the 4S trial trend.This hypothesis has now been revisited among pa-
tients undergoing hemodialysis. In this issue of the
Journal, investigators report results of the 4D (Die
Deutsche Diabetes Dialyse) trial of atorvastatin, 20 mg
daily, versus placebo among 1,255 diabetic hemodial-
ysis patients (7). Allocation to atorvastatin did not
signiﬁcantly reduce the incidence of the composite
outcome of cardiac death, nonfatal myocardial infarc-
tion, and fatal or nonfatal stroke (RR: 0.92; 95% CI: 0.77
to 1.10). It has previously been demonstrated that pa-
tients undergoing hemodialysis tend to be relative
cholesterol absorbers (8). In the present study, anal-
ysis of the effects of atorvastatin among tertiles of CR
showed that the hazard ratios (HR) for the primary
endpoint in the lowest, middle, and highest tertiles
were 0.72 (95% CI: 0.52 to 1.00; p ¼ 0.049), 0.79 (95%
CI: 0.53 to 1.16; p¼0.225), and 1.21 (95%CI: 0.85 to 1.74;
p ¼ 0.287), respectively. Silbernagel et al. (7) conclude
that CR may be useful to distinguish hemodialysis
patients who are “cholesterol synthesizers” (and may
respond to statins) from those who are cholesterol
absorbers (who might beneﬁt from treatments that
inhibit intestinal cholesterol absorption).
Before considering the observed results’ plausibil-
ity, it is important to appreciate that, based on the
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2300observed result (189 vs. 204 events for an RR of 0.89),
about 13% (w1 in 8) of randomly generated sub-
divisions into tertiles would be expected to generate
at least 1 statistically signiﬁcant (p < 0.05) tertile
simply by chance. The ﬁndings in this study are
therefore not as unlikely as they appear based on the
p value of 0.049.
If the mechanism for this observed effect is a
relative lack of LDL-lowering efﬁcacy among choles-
terol absorbers, then this theory might gain support
if there was evidence that variation in cholesterol
absorption inﬂuenced the magnitude of the LDL
cholesterol reductions achieved by atorvastatin
20 mg daily. Speciﬁcally, it would be helpful to know
whether the absolute reductions in LDL (or total)
cholesterol were consistent with the observed trend
towards less beneﬁt among cholesterol absorbers.
Unfortunately, information about changes in lipid
proﬁle in CR tertiles was not provided, so we cannot
answer this question directly. In a previous study of
113 hemodialysis patients, however, patients with
CR above the median had lower LDL cholesterol
concentration than those below the median (162  35
mg/dl vs. 195  40 mg/dl; p < 0.001) (9), so it is
plausible that the absolute reduction in LDL choles-
terol is negatively correlated with CR.
The authors of the present study suggest that in-
hibition of intestinal absorption of cholesterol by
ezetimibe might have been an important reason why,
in contrast to the negative ﬁndings of their 4D trial (7)
and the AURORA (A Study to Evaluate the Use of
Rosuvastatin in Subjects on Regular Hemodialysis: An
Assessment of Survival and Cardiovascular Events)
trial of rosuvastatin in hemodialysis patients (10), the
SHARP (Study of Heart and Renal Protection) trial
showed that simvastatin 20 mg plus ezetimibe 10 mg
daily reduced the risk of major atherosclerotic events
in patients with chronic kidney disease (CKD) (11).
There were, however, major design differences (other
than treatment regimen) among these trials. One that
may have had a critical bearing on the trial ﬁndings
was that the primary outcomes of the 4D and
AURORA trials included substantial numbers of
events that were nonatherosclerotic (and hence could
not have been prevented by lowering cholesterol),
whereas the key outcome of the SHARP trial included
only atherosclerotic events (11,12).The rationale for using the combination of sim-
vastatin 20 mg daily plus ezetimibe 10 mg daily in
the SHARP trial was to achieve the largest possi-
ble LDL cholesterol reduction without a high-dose
statin. In the recently reported results of the
IMPROVE-IT trial (IMProved Reduction of Out-
comes: Vytorin Efﬁcacy International Trial), the
relative reduction in major vascular events result-
ing from the LDL cholesterol reduction achieved
by ezetimibe was equivalent to that predicted for
the same LDL cholesterol reduction achieved by a
statin (13). In the SHARP trial, the mean absolute
reduction in LDL cholesterol was lower at the trial
midpoint among dialysis patients (23 mg/dl) than
among nondialysis patients (37 mg/dl), and—as
predicted by the CTT meta-analysis—the relative
risk reduction in major atherosclerotic events was
smaller in dialysis patients than among nondialysis
patients (RR: 0.90; 95% CI: 0.75 to 1.08 vs. RR: 0.78;
95% CI: 0.67 to 0.91). The relative risk reductions
after adjusting for differences in achieved LDL choles-
terol reductions, however, were similar (p ¼ 0.65)
in dialysis patients (RR: 0.84; 95% CI: 0.62 to 1.13,
per 1 mmol/l [39 mg/dl] reduction in LDL cholesterol)
and in nondialysis patients (RR: 0.78; 95% CI: 0.66
to 0.91, per 1 mmol/l [39 mg/dl] reduction in LDL
cholesterol) (11), consistent with beneﬁt in both
patient groups.
The relevant conclusion, therefore, is that larger
beneﬁts in patients with CKD would be likely if LDL
cholesterol is reduced more intensively than in the
SHARP trial, for example, with the combination of
ezetimibe 10 mg daily and atorvastatin 20 mg or
rosuvastatin 10 mg daily. Irrespective of the physio-
logical importance of cholesterol absorption in pa-
tients with moderate-to-severe CKD, which remains
unclear even after the present study, the trial evi-
dence in this high-risk group of patients is consistent
with a goal of reducing LDL cholesterol by as much as
can be achieved safely.
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